GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382
NCT06032546 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect82/100
StatusTERMINATED
PhasePHASE2
Lead sponsorAbbVie
Last update2026-11-06
Public-record facts
| Intervention | Budigalimab (DRUG), Placebo for Budigalimab (DRUG), ABBV-382 (DRUG), Placebo for ABBV-382 (DRUG), Budigalimab (DRUG) |
|---|---|
| Condition | Human Immuno-deficiency Virus (HIV) Disease |
| Enrollment | 163 |
| Why stopped | Company Decision |
| Results posted | Yes |
Why Beacon surfaced it
- The record is terminated and was updated 2026-11-06.
- It is an interventional PHASE2 study with a named drug/drug/drug/drug/drug intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
- ClinicalTrials.gov indicates posted results are available.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT06032546. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.